Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 15/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921160 | 0.81 | SLC22A12 (0.43) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL11335563 | 0.81 | MEN1 (0.52) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL7190797 | 0.79 | GLO1 (0.65) | — | |
| SCHEMBL16389001 | 0.79 | TRIM24 (0.42) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL16388980 | 0.78 | PTGS1 (0.43) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL16388979 | 0.78 | PTGS1 (0.40) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL27863537 | 0.73 | GLO1 (0.62) | PTGS1PTGS2 | |
| SCHEMBL2556472 | 0.71 | TSHR (0.54) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL29948906 | 0.71 | CA2 (0.41) | CA2PTGS1PTGS2SLC22A12 | |
| SCHEMBL12054691 | 0.71 | CA2 (0.66) | CA2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7651979-B2 | SUCH AS AMMINE (2-AMINO-3-PICOLINE) DICHLOROPLATINUM(II); EFFICIENCY AND SELECTIVITY FOR DESTROYING TRANSFORMED CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20050227290-A1 | Novel coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-13 | — | — | US | disclosed |
| WO-1998046228-A1 | RETINOID ANTAGONISTS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | CA2 4831/4885PTGS1 3983/4885PTGS2 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.